期刊文献+

奥沙利铂联合卡培他滨治疗晚期结直肠癌的疗效观察 被引量:2

下载PDF
导出
摘要 目的探讨奥沙利铂联合卡培他滨治疗晚期结直肠癌的疗效及不良反应。方法选择本院从2010年1月到2011年6月收治的46例晚期结直肠癌的患者用奥沙利铂联合卡培他滨进行化疗。同时选择41例晚期结直肠癌的患者作为对照组仅给予奥沙利铂治疗。结果 46例患者中完全缓解(CR)的有5例、部分缓解(PR)的有20例、稳定(SD)的有16例,进展(PD)的有5例,CR+PR的百分率为总有效率为54.3%。不良反应为消化道反应、骨髓抑制及周围神经炎等。结论奥沙利铂联合卡培他滨治疗晚期结直肠癌有较好的疗效,不良反应轻,患者可以耐受。
出处 《中国实用医药》 2011年第31期173-174,共2页 China Practical Medicine
  • 相关文献

参考文献4

  • 1邱萌,毕锋.XELOX方案治疗老年晚期结直肠癌的临床研究[J].现代预防医学,2008,35(11):2182-2183. 被引量:6
  • 2孙燕,石远凯.临床肿瘤内科手册.第5版.北京:人民卫生出版社,2008,295.
  • 3Wafilk El-Diery,David Metz,et al.Systemic treatment of colorectal cancer.Gastroenterology,2008:134-138.
  • 4Jemal A,Siegel R.,Ward E,et al.Cancer statistics.CA:Cancer.Clin,2009,59:225-249.

二级参考文献11

  • 1Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase 11 trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol. 2003, 21 (7): 1307-1312.
  • 2Schuller J, Gassrly J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administation to colorectal cancer patients [J]. Cancer Chemother Phamacol, 2000, 45 (4) : 291-297.
  • 3Giacchetti S, Perpoint B, Zidani R, et al. Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2000, 18 (1): 136-147.
  • 4de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol, 2000, 18 (16) : 2938-2947.
  • 5Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue [J]. Eur J Cancer, 1998, 34 (8) : 1274- 1281.
  • 6Ishikawa T, Fukase Y, Yamamoto T, et al. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbony1-5-deoxy-5-fluorocytidine(capecitabine)[J]. Biol Pharm Bull, 1998, 21 (7): 713-717.
  • 7Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5- fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [J]. Biochem Pharmacol, 1998, 55 (7): 1091-1097.
  • 8Cassidy J, Tabernero J . XELOX (capecitabine plus oxaliplatin) : active first-line therapy for patients with metastatic colorectal cancer[J].J Clin Oncol, 2004, 22 (11): 2084-2091.
  • 9Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluoroumeil plus leucovorin as firstline treatment in 605 patients with metastatic colorectal cancer: resuits of a randomized phase Ⅲ study [J]. J Clin Oncol, 2001, 19 (8) : 2282-2292.
  • 10Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase Ⅲ study [J].J Clin Oncol, 2001, 19 (2): 4097-4106.

共引文献9

同被引文献20

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部